Compare Merck & Co., Inc. (MRK) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Merck & Co., Inc. trades at $145.85 (market cap $351.28B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Merck & Co., Inc. is far larger — about 965.1× YieldMax Universe Fund of Option Income ETFs's market cap, and Merck & Co., Inc. pays a 2.39% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| MRK | YMAX | |
|---|---|---|
Market Cap | $351.28B | $364M |
Volume | 7,969,665 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $12.98 |
52-Week Low | $82.49 | $7.27 |
Typical Hold Time | 98 Days | 55 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal from moving averages. The ETF maintains weekly dividend distributions but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues, though the fund's structure as a fund-of-funds adds additional cost layers that impact returns.
The outlook remains cautious due to structural concerns and persistent share price decline despite high yield. Investment opportunity exists for income-focused investors willing to accept principal erosion risks, while the primary risk involves unsustainable distribution policy and compounding fees affecting long-term total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
